December 16, 2017 4:32 PM ET

Biotechnology

Company Overview of Gradalis, Inc.

Company Overview

Gradalis, Inc., a biotechnology company, engages in developing, manufacturing, and commercializing drugs, vaccines, tools, and diagnostics primarily for the treatment of cancer. It offers personalized autologous vaccines and bifunctional short hairpin RNA. The company has strategic partnerships with Mary Crowley Cancer Research Centers. Gradalis, Inc. was founded in 2010 and is based in Carrollton, Texas.

2545 Golden Bear Drive

Suite 110

Carrollton, TX 75006

United States

Founded in 2010

Phone:

214-442-8100

Fax:

214-442-8101

Key Executives for Gradalis, Inc.

Chief Executive Officer and President
Co-Founder and Chairman
Co-Founder, Chief Medical Officer and Director
Chief Financial Officer and Vice President of Finance
Chief Medical Officer and Senior Vice President
Compensation as of Fiscal Year 2017.

Gradalis, Inc. Key Developments

Gradalis, Inc. Presents at Noble Financial Capital Markets 13th Annual Small Cap and Emerging Growth Investor Conference, Jan-30-2017

Gradalis, Inc. Presents at Noble Financial Capital Markets 13th Annual Small Cap and Emerging Growth Investor Conference, Jan-30-2017 . Venue: Boca Raton Resort & Club, 501 E Camino Real, Boca Raton, FL 33432, United States.

Gradalis, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 03:30 PM

Gradalis, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 03:30 PM. Venue: The Waldorf Astoria New York, 301 Park Avenue, New York, NY 10022, United States. Speakers: Sunil Joshi, Chief Executive Officer and President.

Gradalis Enters into Collaboration Agreement with Genentech

Gradalis, Inc. has entered into a collaboration agreement with Genentech, Inc. to evaluate the combination of Gradalis' Vigil Engineered Autologous Tumor Cell, or EATC, with Genentech's immune checkpoint, anti-PDL1 antibody, atezolizumab. The planned Phase II clinical trial will be sponsored by Gradalis and evaluate the safety and anti-tumor activity of the combination in women with advanced ovarian cancer. Biomarkers will be used to measure the anti-tumor systemic immune response generated by Vigil alone, atezolizumab alone or the combination of the two agents. Atezolizumab is a monoclonal antibody designed to bind with programmed death-ligand 1 (PDL1), a protein that plays a role in preventing the body's immune system from fighting cancer. This investigational combination immunotherapy is designed to enhance the body's own immune defense against cancer by leveraging these two distinct mechanisms of action. Published preclinical evidence with similar agents provides a strong rationale for this clinical trial. The study will begin in early 2017 and enroll up to 30 patients at multiple centers in the US.Vigil is an investigational cellular immunotherapy technology that combines the concepts of genetic engineering with the science of immuno-oncology, to enable an immune response to cancer cells. A patient's tumor cells are engineered with a plasmid carrying the gene vector for shRNA Furin and GMCSF to elicit a systemic T-cell directed immune response when administered to the patient through intradermal injections. By utilizing the patient's own tumor as the antigen source, Vigil EATC is designed to elicit an immune response that is specifically targeted and broadly relevant to each patient's unique tumor antigens. Vigil EATC is being studied in Ewing's sarcoma and ovarian cancer as a single agent, and in breast cancer, non-small cell lung cancer and melanoma in combination with PDL1 inhibitors.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Gradalis, Inc., please visit www.gradalisinc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.